Asia-Pacific Select ETF South (159687) rose nearly 3% in intraday trading. Asia-Pacific stock markets have experienced the strongest annual start, with Asia leading the global AI competition.
Asia-Pacific Select ETF South (159687) rose nearly 3% in intraday trading, as of the time of publication, had increased by 1.19% to 1.616 yuan, with a trading volume of 91.39 million yuan.
The Asia-Pacific Select ETF by Southern Fund (159687) rose nearly 3% during trading hours, as of the time of writing, it has risen by 1.19%, closing at 1.616 yuan with a trading volume of 91.39 million yuan.
In 2026, Asian stock markets saw a historically strong start, with major stock indices in Japan and South Korea breaking records. Some analysts pointed out that the collective strength of Asian stock markets benefited from the expected improvement in global liquidity environment and the relative advantage of regional economic growth prospects. This also reflects the reassessment of the value of innovation breakthroughs and industrial upgrades in frontier industries such as artificial intelligence, high-end manufacturing, and biotechnology in the Asia-Pacific region by capital markets. Citigroup pointed out that global long-term investors are continuously increasing their holdings of Asian technology stocks due to their important position in the semiconductor supply chain and profit growth potential.
Public information shows that the Asia-Pacific Select ETF (159687; linked fund Class A 021189, Class C 021190) launched by Southern Fund is the only ETF tracking the Asia-Pacific Select Index, covering 11 countries and regions in the Asia-Pacific. The ETF includes high-quality dividend assets in the Asia-Pacific region, such as Toyota, TENCENT, Alibaba, Mitsubishi Group, as well as high-quality semiconductor companies such as TSMC, Samsung, Tokyo Electron, and MediaTek.
Related Articles

RAFFLES INTERIOR (01376) will be suspended briefly starting from the afternoon of January 12th.

CLOVER BIO-B (02197) initiates phase 2 clinical trial for RSV - hMPV - PIV3 respiratory combined vaccine candidate product.

India plans to introduce the world's strictest mobile phone security regulations, requiring Apple Inc. (AAPL.US) and Samsung to open source code.
RAFFLES INTERIOR (01376) will be suspended briefly starting from the afternoon of January 12th.

CLOVER BIO-B (02197) initiates phase 2 clinical trial for RSV - hMPV - PIV3 respiratory combined vaccine candidate product.

India plans to introduce the world's strictest mobile phone security regulations, requiring Apple Inc. (AAPL.US) and Samsung to open source code.

RECOMMEND

Patent Cliff Looms As Pharmaceutical Sector Prepares For A New Round Of Asset Competition
10/01/2026

Goldman Sachs Remains Bullish On China Equities: AI And Overseas Expansion To Drive Earnings, MSCI China Seen Rising 20% In 2026
10/01/2026

“A+H” Popularity Continues As Multiple A‑Share Companies Announce Hong Kong Listings At The Start Of The Year
10/01/2026


